Boston Scientific Reports Third Quarter 2026 Financial Results and Full-Year Guidance

Boston Scientific Corporation announced its financial results for the third quarter of 2026, reporting net sales of $5.138 billion, which represents an increase of 1.5 percent on reported, operational, and organic bases compared to the same period in the prior year. Chairman and Chief Executive Officer Mike Mahoney attributed resilience to global teams amid operational adjustments following a cybersecurity incident reported earlier in August 2026.

Third Quarter Financial Highlights

• Net Sales: $5.138 billion, reflecting a 1.5% year-over-year increase.
• GAAP Net Income: Attributable to common stockholders was $582 million, or $0.40 per share (EPS), compared to $755 million, or $0.51 per share, in the third quarter of 2025.
• Adjusted EPS: Reached $0.73 for the period, compared to $0.75 a year earlier.
• Segment Growth: MedSurg grew 0.6% reported (0.7% operational/organic); Cardiovascular grew 1.9% reported, operational, and organic.
• Regional Performance: United States net sales grew 0.5%; EMEA grew 4.4% reported (6.1% operational); APAC declined 0.6% reported; LACA grew 16.0% reported (10.5% operational).

Operational Developments and Regulatory Clearances

• Clinical Trials: Commenced patient enrollment in the Elite AF clinical trial evaluating the WATCHMAN Elite Left Atrial Appendage Closure Device.
• FDA Clearances: Received U.S. Food and Drug Administration 510(k) clearance for the Navigator Flex Ureteral Access Sheath Set and LithoVue Elite Single-Use Digital Flexible Ureteroscope within the StoneSmart Solutions ecosystem, alongside an expanded size offering for the SEISMIQ Intravascular Lithotripsy Peripheral Catheter.
• Strategic Collaborations: Entered a collaboration with Heartflow, Inc. to advance AI-powered CT-guided planning for percutaneous coronary intervention procedures.

Full-Year and Fourth Quarter 2026 Guidance

• Full-Year 2026: Estimated net sales growth is approximately 4.25% on a reported basis and 3.75% on an organic basis, with adjusted EPS projected between $3.16 and $3.18.
• Fourth Quarter 2026: Net sales are estimated to decline by approximately 3.0% to 1.0% on reported and organic bases, with adjusted EPS estimated between $0.77 and $0.79.

Interested parties can verify these financial disclosures and access webcast details by visiting the investor relations section of the official Boston Scientific website at investors.bostonscientific.com.